Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 2Acute Kidney Injury 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Rare Diseases 1Paraproteinemias 1Neuromyelitis Optica 1Neurologic Manifestations 1Nervous System Diseases 1Neoplasms, Plasma Cell 1Myelitis, Transverse 1Myasthenia Gravis 1Multiple Sclerosis 1Mental Disorders 1Kidney Diseases 1Hematologic Diseases 1Encephalomyelitis, Acute Disseminated 1Diffuse Cerebral Sclerosis of Schilder 1Autoimmune Diseases 1

Interventions

eculizumab 3ravulizumab 2fludarabine 2Cyclophosphamide 2ublituximab 1thymoglobulin 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Sugars 1Rituximab 1Prednisone 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Melphalan 1LFB-R603 1Immunoglobulins, Intravenous 1Etoposide 1Data Collection 1Cytarabine 1Carmustine 1Antilymphocyte Serum 1Alleles 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuromyelitis Optica × Plasma Exchange × Clear all
NCT00004645 2005-06-24

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

Office of Rare Diseases (ORD)

Phase 3 Unknown
22 enrolled

Mental Disorders, Diffuse Cerebral Sclerosis of Schilder, Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myelitis, Transverse, Neurologic Manifestations, Neuromyelitis Optica, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡